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ABSTRACT
T-cell acute lymphoblastic leukemia (T-ALL) is an
aggressive hematological malignancy. The under-
standing of its gene expression regulation and mo-
lecular mechanisms still remains elusive. Started
from experimentally verified T-ALL-related miRNAs
and genes, we obtained 120 feed-forward loops
(FFLs) among T-ALL-related genes, miRNAs and
TFs through combining target prediction.
Afterwards, a T-ALL miRNA and TF co-regulatory
network was constructed, and its significance was
tested by statistical methods. Four miRNAs in the
miR-17–92 cluster and four important genes
(CYLD, HOXA9, BCL2L11 and RUNX1) were found
as hubs in the network. Particularly, we found that
miR-19 was highly expressed in T-ALL patients and
cell lines. Ectopic expression of miR-19 represses
CYLD expression, while miR-19 inhibitor treatment
induces CYLD protein expression and decreases
NF-iB expression in the downstream signaling
pathway. Thus, miR-19, CYLD and NF-iB form a
regulatory FFL, which provides new clues for sus-
tained activation of NF-iB in T-ALL. Taken together,
we provided the first miRNA-TF co-regulatory
network in T-ALL and proposed a model to demon-
strate the roles of miR-19 and CYLD in the T-cell
leukemogenesis. This study may provide potential
therapeutic targets for T-ALL and shed light on
combining bioinformatics with experiments in the
research of complex diseases.
INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) is an aggres-
sive hematological malignancy accounting for about 15
and 25% of pediatric and adult acute lymphoblastic
leukemia (ALL), respectively (1). T-ALL is usually
characterized by proliferation of thymocytes at various
stages of development with high-white blood cell counts,
mediastinal lymph nodes enlargement and central nervous
system involvement (2). Although this neoplastic disorder
originates from the thymus, it will spread throughout all
organs and will be fatal rapidly without therapy.
Compared to the common B-cell lineage ALL, T-ALL
has a worse prognosis in patients historically. Current
multi-agent combination chemotherapy provides an
overall survival rate of 60–70% in children and only
30–40% in adults (3,4). Securing further advances in treat-
ment is dependent on our increasing knowledge on the
factors and mechanism contributing to the malignant be-
haviour of transformed thymocytes. Currently, under-
standing of the etiology of T-ALL has largely come
from the studies of chromosomal abnormalities. Many
chromosomal translocations and gene-speciﬁc alterations
have been identiEed, which include rearrangements of
T-cell receptor genes, ectopic expression of TLX1,
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NOTCH1, PTEN and FBXW7, deletion of CDKN2A and
fusion of NUP214 to ABL1 [review in (5–7)]. Although
the oncogenicity of these genes is well established, under-
standing of the transformational programs and multi-step
pathogenesis of T-ALL remains limited. Especially, the
regulatory networks of T-ALL genes expression are still
elusive.
MicroRNAs (miRNAs) are small noncoding RNAs
of 19–24nt in length that regulate gene expression at the
post-transcriptional level. Long primary miRNAs are ﬁrst
transcribed by RNA polymerase II in the nucleus and
modiﬁed by an enzyme complex containing DROSHA
and DGCR8 to form pre-miRNA. Subsequent cleavage
of pre-miRNA by an RNase III, DICER1, results in
mature miRNA. The mature miRNA may suppress trans-
lation and enhances degradation of target mRNA by
binding to its target site on mRNA 30-UTR regions (8).
MiRNAs play crucial roles in various physiological
processes and are involved in the initiation and progres-
sion of human cancers including T-ALL (9–11). It had
been reported that over-expression of miR-125b would
induce leukemia independently in a mouse model (12).
High expression of miR-196b was found in leukemia
with aberrant activation of HOXA genes (13). MiRNA
expression proﬁles in ALL have been identiﬁed by
several groups (14,15). Human miR-17–92 cluster is sufﬁ-
cient to promote leukemogenesis in Notch1-induced
T-ALL in vivo (16), and over-expression of pri-miR-
17–92 in T-ALL cell lines will reduce E2F1 protein level
to enhance the survival of leukemic T-cells (17). Recently,
miR-451 and miR-709 were demonstrated as potent sup-
pressors of oncogenesis in Notch1-induced mouse T-ALL
(18). Although a few studies reported the aberrant expres-
sion and function of miRNAs in T-ALL, the miRNA
regulatory network in T-ALL is a key question to be ad-
dressed urgently.
Transcription factors (TFs) are key regulators
controlling the transcription of target genes by binding
to speciﬁc DNA sequences on the promoter of target
genes. Both the TFs and miRNAs are regulators of gene
expression, and they may mutual regulate each other to
form feedback loops, or they regulate the same target gene
to form a feed-forward loop (FFL). It has been reported
that hundreds of potential miRNA-mediated feedback
and FFLs are available at the genome level (19–21).
Several feedback loops and FFLs have been experimen-
tally veriﬁed, such as PITX3 and miR-133b in midbrain
dopamine neurons, cyclin D1 and miRNA-17/20 feedback
loop in breast cancer and TP53/miR-106b/E2F FFL in
cell proliferation (22–24). Moreover, several databases
about miRNA-TF feed-forward regulatory circuits have
been developed (25,26). Recently, we have identiﬁed 32
FFLs and constructed the miRNA-TF co-regulatory
network in schizophrenia, which is the ﬁrst study
investigating the miRNA-TF regulatory network for a
human complex disease (27).
In this study, we aim to identify important miRNAs
and regulatory modules in T-ALL. Starting from collect-
ing T-ALL-related miRNAs and predicting the miRNA
and TF targets based on a combined strategy, then,
we constructed a miRNA-TF co-regulatory network spe-
ciﬁcally for T-ALL and found some hub regulators, genes
and their regulation in the network. To verify the reliabil-
ity of regulatory modules and network, we experimentally
conﬁrmed that the hub miR-19 indeed inhibited hub
gene CYLD in T-ALL, and CYLD, miR-19 and NF-kB
participated in a FFL. Consequently, this study enhanced
the understanding of regulatory mechanism of T-ALL and
also provided a new approach with bioinformatics
guidance in studying of cancers and other complex
diseases.
MATERIALS AND METHODS
T-ALL candidate genes and miRNAs
To analyze the miRNA-TF regulation in T-ALL, we col-
lected and curated the T-ALL-related miRNAs and genes
in the following two criteria: (i) Those have been veriﬁed
the functions and aberrant expression in T-ALL patients,
cell lines or animal models by experiments. (ii) Those have
been clearly described with pivotal roles in T-ALL review
literatures. For comparison, we compiled two control
miRNA data sets: miRNAs expressed in thymus
(thymus miRNAs) and non-thymus tissues (non-thymus
miRNAs). Thymus miRNAs were collected from
miRNA microarray expression studies and a miRNA
survey study (15,28). Non-thymus miRNAs were those
reported not expressed in thymus from a miRNA expres-
sion proﬁle (29). To avoid the redundancy, we removed
T-ALL-related miRNAs (T-ALLmiRNAs) from thymus
miRNAs and thymus miRNAs from non-thymus
miRNAs. We obtained information of genomic locations,
host genes and conservations of these miRNAs from
miRBase (30) (Release 16: Sept 2010, genome assembly:
NCBI 37.1).
Target prediction of miRNAs and TFs
MiRNA targets were predicated mainly by combinatorial
utilization of four different web-based databases. We
chose the overlapped predicted targets from TargetScan
(TargetScan 5.1, April 2009) and miRanda (Release Date:
September 2010) based on the evolutionary conservation
among mammalias. Then, we merged the results with the
reported miRNA targets from miR2Disease (Release
Date: December 2010) and TarBase (TarBase_V5, Jun
2008) (31–34). The relationships between them can be
described as (TargetScan\miRanda)[miR2Disease[Tar
Base. We also collected the experimentally conﬁrmed
targets for the T-ALL miRNAs by literature curation
and combined them with the above results. MiRNAs clus-
tered in a genomic region are preferentially co-expressed
and miRNAs in gene region are usually co-expressed with
their host genes, as a part of the same transcription unit.
Used the similar strategy used in our previous work, we
chose a 5kb maximum inter-miRNA distance as the
miRNA cluster criteria and 5kb upstream of the host
gene, miRNA precursor or miRNA cluster as the
putative promoter region for miRNA in a genic region,
intergenic region or miRNA cluster, respectively (27).
We retrieved predicted transcription factor binding sites
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required them to be conserved among humans, mice and
rats. To further reduce the false-positive prediction, we
used Z score of 2.33 as a cutoff for high-quality TFBSs.
A TFBS was considered associated with a target gene
when it was in the gene’s 5k promoter region and its Z
score was >2.33.
FFLs and statistics tests
FFLs were constructed among TFs, miRNAs and T-ALL
genes (T-ALLGenes) according to the procedure in
Figure 1. Two methods were used to evaluate the signiﬁ-
cance of FFLs among T-ALLmiRNAs, T-ALLGenes and
TFs as our previous study (27). Here, we described them
simply. First, we used Fisher’s exact test to compare the
observed FFLs from T-ALLmiRNAs with those from
thymus miRNAs or non-thymus miRNAs. Second, we
ran randomisation processes to extract the same number
of random miRNA target pairs out of all predicted target
pairs of the T-ALLmiRNAs and then calculated the
number of FFL among miRNAs, random targets and
TFs. We repeated this 10000 times and set the P-value
as the proportion of the random results that had no less
than the number of FFLs observed in the set of
T-ALLmiRNAs and T-ALLGenes.
Network and hub analysis
Networks were presented with Cytoscape software (36)
(version 2.6.1). In the miRNA-TF-mediated network, we
deﬁned node as a hub gene or miRNA when it directly
linked to more than eight total nodes in the network. We
used the Functional Annotation Tool of DAVID (37)
(DAVID 6.7, http://david.abcc.ncifcrf.gov) to analyze
networks and pathways for a set of genes. We set
P-value<0.01 as the cutoff for enriched GO terms or
pathways identiﬁed in Gene Ontology and KEGG.
Cell lines and culture
Human tumor cell line Jurkat (acute T-cell leukemia),
Molt-4 (human T-cell leukemia), HepG2 (hepatocarcinoma)
and embryonic kidney cell line HEK-293T were
purchased from the China Center for Type Culture
Collection (CCTCC, China) and maintained in
RPMI-1640 Medium (Hyclone, USA) containing 10%
fetal bovine serum (FBS), with 100 U/ml penicillin and
100 U/ml streptomycin. All the cells were grown in an at-
mosphere of 5% CO2 at 37 C.
RNA extraction and qRT–PCR
Whole RNAs were isolated from cell lines and tissue
samples using TRIzol (Invitrogen, USA), and the
protocol was done according to the manual of TRIzol.
cDNAs were synthesized from 2mg of total RNA with
RevertAid
TM First-strand cDNA Synthesis Kit
(Fermentas, USA) in a 50ml volume {2mg total RNA,
5nM reverse transcription primer [random primers for
U6 srRNA and miRNA speciﬁc primers (Bulge-Loop
TM
miRNA qPCR primers from RiboBio, China) for
miRNA], 0.8U/ml reverse transcriptase, 4U/ml inhibitors,
0.2mM dNTP mix}. Real time-PCR was carried out with
the reagents of SYBR Green Master (Roche, Germany) in
20ml reaction volume (10ml SYBR Green Master, 500nM
forward primers, 500nM reverse primers and 2ml cDNA
template) by using StepOnePlus
TM Systems (ABI, USA)
with the following protocol: 95 C for 20s; 40 cycles of
Figure 1. Workﬂow of the miRNA-TF regulatory network construction in T-ALL. First, using sequence analysis strategy, we built two independent
pipelines for the construction of a transcription factor and miRNA regulatory network. Then, merged them into a miRNA-TF regulatory network.
Nucleic Acids Research, 2012,Vol.40, No. 12 520395 C for 10s, 60 C for 20s, 70 C for 5s. Data analysis
was performed using the 2Ct method (38).
Transfection assay
The mimics and inhibitors of miR-19, negative control
miRNA were obtained from Ribobio (Guangzhou,
China); Transfection was performed using X-treme
GENE siRNA Transfection Reagent (Roche, Germany)
according to the manufacturer’s instructions. The cells
were seeded in six-well plates (1 10
5 cells/well) with
1.5ml RPMI-1640 medium (Hyclone, USA) contain-
ing 6% FBS, without penicillin/streptomycin.
The miR-19 mimics/inhibitors/negative control groups
were prediluted in 250ml Opti-MEM I Reduced
Serum Medium (Gibco, USA). Subsequently, 5–10ml
X-tremeGENE siRNA Transfection Reagent was
diluted in 250ml Opti-MEM I Reduced Serum
Medium and combined with the miR-19 dilution
solution by Opti-MEM I Reduced Serum Medium.
The 500ml mixture was incubated for 20min at room
temperature and added to the cells.
Cell survival assay
Thecellswereseededintothe96-wellplatesandtransfected
with the miR-19 mimics/inhibitors/negative control, which
was performed using X-tremeGENE siRNA Transfection
Reagent (Roche, Germany) according to the manufac-
turer’s instructions. After 24 or 48h of transfection,
WST-1 solution (Roche, Germany) was added, and the
cell number was detected at 450nm using the Tecan
Sunrise microplate reader (Mannedorf, Switzerland).
Relative cell survival=Asample/Auntreat control.
Western blot
The cells cytoplasm or nucleus lysates after transfection
with miR-19 mimics/inhibitors/negative were separated by
sodium dodecyl sulfate–polyacrylamide gel electrophor-
esis (SDS–PAGE), followed by the transfer onto nitrocel-
lulose membranes. The membranes were blocked in TBST
(Tris-buffered saline with 0.1% Triton X-100) containing
5% non-fat milk and probed with rabbit anti-human
CYLD (Abcam, UK) or NF-kB P65 (SantaCruz, USA)
or Histone 2A.X (Abcam, UK) antibodies or mouse
anti-human b-actin antibody (SantaCruz, USA). After in-
cubation with the secondary antibody (Li-Cor, USA),
conjugated with horseradish peroxidase, membranes
were extensively washed with TBST, and positive signals
were visualized by Odyssey Two-Color Infrared Imaging
System (Li-Cor, USA). After indicated, the level of CYLD
and P65 protein was quantitated by densitometric analysis
using Quantity One software (Bio-Rad, USA). The
results were expressed as the ratio of the band density of
CYLD to that of corresponding b-actin or P65 to that of
corresponding Histone 2A.X.
Luciferase reporter assay
A fragment of 30-UTR of CYLD DNA containing the
target sequence (TTTGCAC) of miR-19 was ampliﬁed
by PCR (sense 50-GCCTCGAGGGCAAAGAAACTGA
AGGC-30, anti-sense 50-CAGCGGCCGCCTGCTAAAT
ACCCTAATC-30; Bioladder, China). The PCR products
were gel puriﬁed, digested and inserted into pMD18-T
Vector (Takara) and then conﬁrmed by PCR. The
plasmids were extracted and digested by XhoI and NotI.
Then, the produces were inserted into the digested
psiCHECK-2 vectors (Promega, USA) between the XhoI
and NotI sites. The inserted sequences were conﬁrmed by
sequencing.
The HEK293T cells were seeded in 12-well plates with
800ml Opti-MEM I Reduced Serum Medium without
penicillin/streptomycin. Plasmids and miR-19 mimics/
inhibitors/negative control were cotransfected into
HEK293T cells with Lipo 2000 Transfection Reagent
(Invitrogen, USA) according to the manufacturer’s
protocol. The mimics of miR-19 and luciferase reporter
vectors were prediluted in 100ml Opti-MEM I Reduced
Serum Medium. Afterwards, 2ml Lipo2000 Transfection
Reagent was diluted in 100ml Opti-MEM I Reduced
Serum Medium and combined with the miR-19 dilution
solution by Opti-MEM I Reduced Serum Medium. The
200ml mixture was incubated for 20min at room tempera-
ture and added to cells. The ﬁnal miR-19 concentration
was 50nM. The medium was adjusted to 10% FBS after
incubation for 6h.
The luciferase reporter assay was performed according
to the manufacturer’s instructions of Dual-Luciferase
Report Assay Kit (Promega, USA). The cells were col-
lected after transfection for 48h, and 75ml( 5 104) cells
were lysed with 75-ml luciferase reagent for 10min in the
white plate. The plate was read by Tecan luminescence
plate reader (Mannedorf, Switzerland) as the activity of
ﬁreﬂy luciferase. Then, 75-ml dual luciferase reagent was
added into the plate and mixed for 10min. The plate was
read as the activity of renilla luciferase. Result=Arenilla
luciferase/Aﬁreﬂy luciferase.
RESULTS
T-ALL-related miRNAs, genes and TFs
Aiming to explore the miRNA and TF co-regulatory
network in T-ALL, it is indispensable to construct the
feedback loop between miRNA and TF, and FFL
among miRNA, TF and T-ALL genes (Figure 1). On
one hand, we compiled 67 T-ALL-related genes
(T-ALLGenes) from literatures, which play critical roles
with aberrant expression in T-ALL patients, cell lines or
animal models. On the other hand, after exhausted
searching for miRNA expression proﬁles in T-ALL, we
collected and curated 36 T-ALL-related miRNAs
(T-ALLmiRNAs), which are experimentally veriﬁed to
be crucial and aberrant expression in T-ALL (14,39,40).
Furthermore, for comparison, we also collected 109
miRNAs expressed in thymus (thymus miRNAs) and
113 miRNAs, which were not expressed in thymus from
published miRNA expression proﬁles (non-thymus
miRNAs).
According to uniﬁed names in miRBase (30) (http://
mirbase.org), the 36 T-ALL-related mature miRNAs, we
collected match to 42 precursor miRNAs. Among the 42
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conserved in Chordata, 1 is even conserved in
Drosophila and 6 are mammal-speciﬁc (Table 1). Ten
miRNAs are in host genes and others are intergenic
miRNAs. Thirteen T-ALLmiRNAs (31%) are found
downregulated in T-ALL, while others are upregulated.
It is notable that all members of the two notorious
tumor-related miRNA clusters (miR-17–92 and
miR-106–363) are included in our T-ALLmiRNA list.
After compiling the T-ALL gene and miRNA lists, we
tried to predict the targets of T-ALLmiRNAs in
T-ALLGenes. We mainly obtained the miRNA targets
by combinatorial utilization of four different databases
(see ‘Materials and Methods’ section), including predicted
results from TargetScan (http://www.targetscan.org),
miRanda (http://www.microrna.org) and experimental
veriﬁed targets from miR2Disease (http://www
.mir2disease.org./) and TarBase (http://diana.cslab.ece
.ntua.gr/tarbase) (31–34). We also collected the
published experimentally reported targets of the 42 col-
lected T-ALL miRNAs by literature curation. Among
the 67 T-ALLGenes, 47 are predicted targets of 39
T-ALLmiRNAs (Supplementary Figure S1). Seven of
the 47 targeted T-ALLGenes (i.e. PTEN, CYLD,
BCL2L11, MCL1, RUNX1, CDKN1A and JAK1) are
targeted by more than 8 T-ALLmiRNAs. Among the
T-ALLmiRNAs, miR-582 targets the most (21) genes in
the T-ALLGene list, followed by miR-30e and miR-34b,
each targets 13 T-ALLGenes. The two notorious tumor-
related miRNA clusters (miR-17–92 and miR-106–363),
which target 17 and 18 T-ALLGenes, respectively
(Supplementary Table S1).
To obtain the TF regulatory relationship for our
miRNA-TF co-regulatory network, we further predicted
the TF targets in our compiled T-ALLGenes and
T-ALLmiRNAs. Under a stringent criteria and
Table 1. Basic information of T-ALL-related miRNAs and their aberrant expression in T-ALL
T-ALLmiRNA Location (Chr:start-end[strand]) Host gene Taxonomy
conservation
Expression in
T-ALL
let-7e chr19:52196039-52196117[+] Intergenic Chordata #
miR-100 chr11:122022937-122023016[ ] LOC399959 Metazoa #
miR-106a chrX:133304228-133304308[ ] Intergenic Mammalia "
miR-125b miR-125b-1 chr11:121970465-121970552[ ] LOC399959 Vertebrata #
miR-125b-2 chr21:17962557-17962645[+] C21orf34 Vertebrata #
miR-130b chr22:22007593-22007674[+] Intergenic Vertebrata "
miR-142 chr17:56408593-56408679[ ] Intergenic Vertebrata "
miR-148a chr7: 25989539- 25989606[ ] Intergenic Vertebrata "
miR-151 chr8:141742663-141742752[ ] PTK2 Mammalia #
miR-17 chr13:92002859-92002942[+] Intergenic Vertebrata "
miR-181a miR-181a-1 chr1:198828173-198828282[ ] Intergenic Vertebrata #
miR-181a-2 chr9:127454721-127454830[+] Intergenic Vertebrata #
miR-181b-1 chr1:198828002-198828111[ ] Intergenic Vertebrata "
miR-181c chr19:13985513-13985622[+] Intergenic Vertebrata "
miR-18a chr13:92003005-92003075[+] Intergenic Vertebrata "
miR-18b chrX:133304071-133304141[ ] Intergenic Vertebrata "
miR-193a chr17:29887015-29887102[+] Intergenic Vertebrata "
miR-196a miR-196a-1 chr17:46709852-46709921[ ] Intergenic Vertebrata #
miR-196a-2 chr12:54385522-54385631[+] Intergenic Vertebrata #
miR-196b chr7:27209099-27209182[ ] Intergenic Vertebrata #
miR-19a chr13:92003145-92003226[+] Intergenic Vertebrata "
miR-19b miR-19b-1 chr13:92003446-92003532[+] Intergenic Vertebrata "
miR-19b-2 chrX:133303701-133303796[ ] Intergenic Vertebrata "
miR-204 chr9:73424891-73425000[ ] TRPM3 Vertebrata "
miR-20a chr13:92003319-92003389[+] Intergenic Vertebrata "
miR-20b chrX:133303839-133303907[ ] Intergenic Vertebrata "
miR-223 chrX:65238712-65238821[+] Intergenic Vertebrata "
miR-29a chr7:130561506-130561569[ ] Intergenic Vertebrata #
miR-29b-1 chr7:130562218-130562298[ ] Intergenic Vertebrata #
miR-30e chr1:41220027-41220118[+] NFYC Vertebrata "
miR-331 chr12:95702196-95702289[+] Intergenic Mammalia "
miR-34b chr11:111383663-111383746[+] LOC728196 Chordata "
miR-363 chrX:133303408-133303482[ ] Intergenic Vertebrata "
miR-365 miR-365-1 chr16:14403142-14403228[+] Intergenic Vertebrata "
miR-365-2 chr17:29902430-29902540[+] Intergenic Vertebrata "
miR-424 chrX: 133680644-133680741[ ] Intergenic Mammalia "
miR-582 chr5:58999432-58999529[ ] PDE4D Mammalia "
miR-708 chr11:79113066-79113153[ ] ODZ4 Mammalia "
miR-92a miR-92a-1 chr13:92003568-92003645[+] Intergenic Chordata "
miR-92a-2 chrX:133303568-133303642[ ] Intergenic Chordata "
miR-93 chr7:99691391-99691470[ ] MCM7 Vertebrata "
miR-99a chr21:17911409-17911489[+] C21orf34 Vertebrata #
Taxonomy conservation: mammals: (human, mouse, rat, dog); vertebrates: (human, mouse, rat, dog, chicken, frog, ﬁsh); chordata: (human, mouse,
chicken, ﬁsh, Ciona); metazoa: (human, mouse, chicken, ﬁsh, Ciona, ﬂy).
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for the predicted TFBS data in UCSC Genome Browser,
we obtained 313 TFBSs on the promoter regions of 56 of
the 67 T-ALLGenes and 242 TFBSs on the predicted pro-
moters of 33 of the 42 T-ALLmiRNAs. These TFBSs es-
tablished a complex relationship between T-ALL-related
genes, TFs and miRNAs. Referring to MSigDB database
(41), we extracted all the TFs corresponding to TFBSs.
Thus, we obtained the miRNA targets and TF targets in
T-ALLGenes.
FFLs in T-ALL
Since the targets of miRNAs and TFs were predicted
in T-ALLGenes, we obtained 120 FFLs among
T-ALLGenes, T-ALLmiRNAs and TFs by integrating
the joint regulatory relationships of T-ALLmiRNAs and
TFs to T-ALLGenes (Supplementary Table S2), which
contain 24 T-ALLGenes, 26 T-ALLmiRNAs and 33
TFs. To evaluate the enrichment of these observed FFLs
in the T-ALL network, we performed statistical tests with
two approaches. First, we compared the FFLs obtained
from T-ALLmiRNAs with those from thymus miRNAs
or non-thymus miRNAs and evaluated the signiﬁcance by
Fisher’s exact test (Table 2). Both of the P-values of the
two comparisons are highly signiﬁcant (<0.01), which
indicate that there were signiﬁcantly more FFLs in
T-ALLmiRNAs with T-ALLGenes than in thymus or
non-thymus miRNAs with T-ALLGenes. We noticed
that the P-value in the comparison between
T-ALLmiRNAs and thymus miRNAs was larger than
the comparison between T-ALLmiRNAs and non-thymus
miRNAs, which likely represent that some thymus
miRNAs in our data set may be highly associated with
T-ALL but not yet been reported.
Second, we ran 10000 random simulations (see
‘Materials and Methods’ section) to test the signiﬁcance
of the observed FFLs in T-ALL. In each run, since there
were 270 miRNA-target pairs between T-ALLmiRNAs
and T-ALLGenes, we randomly selected 270
miRNA-target pairs out of all target pairs of the 42
T-ALLmiRNAs and calculated the number of FFLs
among TFs, T-ALLmiRNAs and those randomly
selected target genes. We found that the numbers of
FFLs in all the simulations were less than our observed
number of FFLs in T-ALLmiRNAs and T-ALLGenes,
indicating that our observed FFLs signiﬁcantly differ
from that by chance.
MiRNA and TF co-regulatory network in T-ALL
Besides the miRNA-TF co-regulate one target as in a FFL
module, miRNA and TF may also regulate each other to
form a feedback loop. In the compiled T-ALLmiRNAs,
we identiﬁed three T-ALLmiRNA-TF mutual regulatory
loops, which all components are included in our above
FFLs (Supplementary Table S3). We merged the three
T-ALLmiRNA-TF loops into FFLs and constructed a
miRNA-TF co-regulatory network for T-ALL. To
simplify the graph, we merged the miR-19a/b to miR-19
and NFKB1/2 to NFKB. After removing a few isolated
nodes, the network contains 21 T-ALLmiRNAs, 21
T-ALLGenes, 28 TFs and 176 links (edges) between
these molecules (nodes) (Figure 2). Among the 21
T-ALLmiRNAs in the network, most of (16/21) them
are upregulated in T-ALL. Moreover, there were three
pairs of regulatory relationships (miR-19 represses
NOTCH1, PTEN and BCL2L11) that had been experi-
mentally conﬁrmed in T-ALL (16). MYC was veriﬁed as
a potent and direct transcriptional activator of miR-17–
92, which is consistent with the same regulatory relation-
ship in our network (42).
Subnetworks for hubs in the miRNA-TF regulatory
network
According to the criteria described in the ‘Materials and
Methods’ section, we selected four hub genes (HOXA9,
CYLD, BCL2L11 and RUNX1) and four hub miRNAs
(miR-19, miR-20a, miR-92a-1 and miR-17) in Figure 2
T-ALL miRNA-TF regulatory network. All the four
hub genes are related to apoptosis, inﬂammation, prolif-
eration and differentiation of T cell. It is interesting that
the four hub miRNAs are all from the notorious
cancer-related miRNA cluster miR-17–92, and they are
all upregulated in T-ALL (Supplementary Figure S2A).
To further investigate the regulation of these hub genes
and miRNAs, we extracted their subnetworks that include
all their directly linked molecules in the miRNA-TF regu-
latory network (Figure 3). CYLD stood out as a
promising tumor suppress gene that involved in NF-kB
pathway, which is regulated by ﬁve TFs and ﬁve
T-ALLmiRNAs, all from the two cancer-related miRNA
clusters (Supplementary Figure S2B). MiR-19 is poten-
tially regulated by 12 TFs (e.g. NFKB, MYC, REL,
CREB1 and STAT5A) and represses the expression of
six important cancer genes, such as NOTCH1, PTEN,
BCL2L11, HOXA9 and CYLD. We extracted the pre-
dicted targets of these four miRNAs on human genome
and found 794, 856, 854 and 556 target genes for them,
respectively. The enriched pathways of these predicted
targets of the four hub miRNAs were examined by the
DAVID Functional Annotation Tool (see ‘Materials
And Methods’ section). Interestingly, we found many
pathways related to proliferation, differentiation, metab-
olism, cancer and intracellular signaling cascade
(Supplementary Table S4), which suggested that the four
hub miRNAs were important in cancer development
including T-ALL. We also examined the enriched GO
terms of these predicted targets. Among the enriched
GO terms, several terms were related to the occurrence
and development of T-ALL, such as regulation of
Table 2. Statistics of FFLs identiﬁed by miRNAs in T-ALLmiRNAs
and T-ALLGenes
miRNA data set No. of
miRNAs
FFLs P-value
T-ALL miRNA 42 120
Thymus miRNA 109 160 0.002
Non-thymus miRNA 113 33 <2.2 E-16
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cascade, cell apoptosis and proliferation (Supplementary
Table S5).
High expression of miR-19 in T-ALL patients and
T-leukemia cell lines
As predicted several hub miRNAs, genes and modules
among them in the T-ALL miRNA-TF co-regulatory
network, we further validated the different expression
and regulation for a speciﬁc hub miRNA and gene in
T-ALL to partially verify our network by experiments.
The cancer-related miRNA cluster miR-17–92 contains
six miRNAs: miR-17-5p, miR-18a, miR-19a, miR-19b,
miR-20a and miR-92a. Among them, miR-19 is one of
the most important and well-studied miRNAs in different
cancers including T-ALL. MiR-19a and miR-19b have the
same seed sequence, and there is only one nucleotide dif-
ference in their mature sequences. We detected the expres-
sion of miR-19a and miR-19b in clinical samples and
found very similar expression level of them (Figure 4A).
Thus, miR-19 was applied to represent both miR-19a and
miR-19b in the following context.
To test the expression level of miR-19 in leukemic
patients, we chose 23 diagnosed patients, which contain
11 T-ALL, 3 B-ALL and 9 acute myeloid leukemia (AML)
cases. The results showed that the expressions of miR-19
in T-ALL/B-ALL/AML patients were all signiﬁcantly
higher than health donors, and T-ALL patients had the
highest expression (Figure 4B). Furthermore, we
examined the miR-19 expression in several cell lines.
Compared to the low-miR-19 expression in non-tumor
HEK-293T cells, miR-19 was found highly expressed in
tumor cell lines, such as Jurkat (T-cell acute leukemia),
Molt-4 (Human T cell leukemia) and HepG2
(Hepatocarcinoma; Figure 4C). The highest expression
of miR-19 was found in Jurkat cell line, which was con-
sistent with the investigation in patient samples.
To test the oncogenic role of miR-19, the cell survival
level was detected in Jurkat cells. The cells were incubated
with miR-19 mimics and inhibitors for 0, 24 and 48h
(Figure 4D). Our results showed that transfection of
miR-19 mimics increased the survival level of Jurkat
cells, while the inhibitors of miR-19 transfection decreased
the survival level of the Jurkat cells. The effect was more
signiﬁcantly stronger after transfection 48h than 24h. In
addition, we used different concentrations of miR-19
mimics/inhibitors and found that the relative cell
survival level of Jurkat cells was increased when the con-
centration of the miR-19 mimics was enhanced
(Figure 4E). The opposite phenomenon was found when
dosages of the miR-19 inhibitors were increased
(Figure 4F).
MiR-19 inhibits the expression of CYLD and induces
downstream NF-iB
To ﬁnd out the oncogenic role of miR-19, we investigated
the expression level of CYLD protein through transfection
with miR-19 mimics/inhibitors in Jurkat, Molt-4 and
HEK293T cells. In all these three kinds of cells,
overexpression of the miR-19 decreased the expression
Figure 2. miRNA and TF co-regulatory network in T-ALL. Round rectangle nodes: upregulated T-ALLmiRNAs; hexagon nodes: downregulated
T-ALLmiRNAs; ellipse nodes: T-ALL candidate genes; triangle nodes: TFs. Bigger nodes represent hubs in network. T shape edge: miRNA
repression; arrow shape edge: transcriptional activation/repression. Thick lines denote regulatory relationships that are supported by experimental
reports.
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in a dosage-dependent manner, and the expression level of
CYLD protein was signiﬁcantly lower transfected with
50nM than 25nM (Figure 5A).
The expression level of CYLD protein was increased in
Jurkat and Molt-4 cells while blocking of miR-19
compared with the negative control, X-tremeGENE
siRNA Transfection Reagent and untreated group, but
no obvious change in HEK-293T cells (Figure 5B). The
expression level of CYLD protein was signiﬁcantly higher
when transfected with 100nM than 50nM’s miR-19 in-
hibitors. We have repeated these experiments three
times, and all the quantiﬁed western blot data of CYLD
were presented in Supplementary Figure S3 (A, B, E, F, I
and J).
Since CYLD plays a predominant role in the negative
regulation of NF-kB (43), we further examined the impact
of CYLD on NF-kB activation by detecting the level of
nucleus NF-kB P65 protein in the three cell lines trans-
fected with miR-19 mimics/inhibitors. After transfected
with miR-19 mimics, the results indicated that the level
of nucleus NF-kB P65 protein was clearly increased
compared with negative control, and the effect of 50nM
mimics was stronger than that of 25nM (Figure 5C).
While the expression level of P65 was clearly decreased
when transfected with miR-19 inhibitors compared with
the control (Figure 5D). These experiments were also
repeated at least three times, and all the quantiﬁed
western blot data of NF-kB were presented in
Supplementary Figure S3 (C, D, G, H, J and K). Since
the expression of cytokine IL-6 mRNA relied on NF-kB
(44); here, we also found that the expression of IL-6
was decreased after transfecting miR-19 inhibitor
(Supplementary Figure S4).
MiR-19 inhibits CYLD expression by binding to the
30UTR conservative sites of its mRNA (Figure 5E), to
further conﬁrm that CYLD is directly regulated by
miR-19, we performed miRNA luciferase assay in four
groups (Figure 5F). The ﬁrst group only contains
CYLD 30UTR ﬁreﬂy luciferase vector, and no obvious
ﬂuorescence changing was found. The second group trans-
fected with negative miRNA also showed no signiﬁcant
change in ﬂuorescence quenching. The third group trans-
fected with miR-19 mimics, its ﬂuorescence intensity ex-
tremely signiﬁcantly decreased compared with the ﬁrst two
groups. The fourth group transfected with miR-19 inhibi-
tors, we could not ﬁnd signiﬁcant ﬂuorescence intensity
changes.
Figure 3. Subnetworks of the eight hubs in our miRNA-TF co-regulatory network. The subnetworks were drawn by all the direct linked nodes for
the hubs. (A) CYLD; (B) HOXA9; (C) RUNX1; (D) BCL2L11; (E) miR-17; (F) miR-19; (G) miR-20a; (H) miR-92a-1.
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In this study, we constructed a miRNA and TF
co-regulatory network speciﬁcally for T-ALL, which
provided important insights into the etiology of T-ALL.
Our analysis indicated that this regulatory network is sig-
niﬁcantly enriched in T-ALL, and some published results
also conﬁrmed the reliability of the network.
Furthermore, we discovered miR-19 inhibits CYLD in
T-ALL for the ﬁrst time. We tentatively proposed that
miR-19 and CYLD play critical regulatory roles in the
NF-kB pathway, while in turn NF-kB may bind to their
upstream promoter regions and regulate their transcrip-
tions. Our results identiﬁed gene regulatory network
modules and extended the understanding of gene regula-
tion mechanism in T-ALL.
In the miRNA-TF co-regulatory network, we identiﬁed
four hub genes (CYLD, HOXA9, BCL2L11 and RUNX1)
and four hub miRNAs (miR-19, miR-17, miR-92a-1 and
miR-20a) in the miR-17–92 cluster, all of these hubs likely
play important regulatory roles in T-ALL. The hub genes
are fragile points in the regulatory network with many
nodes linked to them and mutation of them may deadly
disrupt the normal function. Meanwhile, we also con-
ﬁrmed some well-studied T-ALL candidate genes (e.g.
NOTCH1, PTEN, FBXW7 and LMO2) and nuclear
TFs (e.g. CREB1, MYC, STAT and NF-kB) in the
miRNA-TF network. Many of them involved in import-
ant pathways, such as PI3K/AKT pathway, NOTCH
pathway, NF-kB pathway and JAK pathway (45–49).
Some targets of the miRNAs in our network participated
in multiple signal pathways, which may establish
cross-talks among these pathways. Therefore, our
network offered more details of why some genes
mutated lead to T-ALL and provided potential targets
for treatment.
As detected by previous studies and our results,
members of the miR-17–92 cluster were found aberrantly
upregulated in T-ALL patients and most of hematological
malignant cell lines (50–52). In our network, miR-19 is a
hub miRNA regulate 6 T-ALLGenes and targeted by 12
TFs. The predicted targets of miR-19 were enriched in
many important signaling pathways, such as MAPK sig-
naling pathway, Wnt signaling pathway and TGF-b sig-
naling pathway (Supplementary Table S4). Several groups
have identiﬁed that miR-19 was signiﬁcantly upregulated
in Notch-induced T-ALL, and its target genes like PTEN,
BCL2L11 (Bim) and NOTCH1 have been identiﬁed in
mouse models (16). It had been reported that deletion of
the complete miR-17–92 cluster repressed the
MYC-induced oncogenesis (53,54). This effect was
rescued by reintroduction of the full cluster, but not by
the cluster lacking miR-19. Recovery of miR-19 largely
rescued the tumorigenicity, which identiﬁed miR-19 as
the most important oncogenic miRNA in the miR-17–92
cluster (55).
To explore the regulatory mechanism of T-ALL, we
proposed a model to demonstrate the regulation of
miR-19 in T-ALL-signaling pathways by integrating the
results of our miRNA-TF regulatory network with the
canonical T-cell development and T-ALL-signaling
pathways (Figure 6). In T-ALL patients and hematolo-
gical malignant cell lines, miR-19 was signiﬁcantly
Figure 4. MiR-19 is high expressed in leukemia patients and tumor cell lines. (A) The similar expression of miR-19a and miR-19b in peripheral
blood mononuclear cells (PBMCs) of ALL patients. U6 snRNA was used as an internal control. (B) Expression of miR-19 in T-ALL/B-ALL/AML
patients and health donors. (C) Expression of miR-19 in human tumor cell lines: HepG2 (Hepatocarcinoma), Jurkat (T cell acute leukemia), Molt-4
(Human T cell leukemia) and normal cell line HEK-293T (Human Embryo Kidney cell). (D) Changing of the relative absorbance by WST assay in
the Jurkat cells treated with miR-19mimics/inhibitors for 0/24/48h. (E) Relative cell survival level of Jurkat cells after transfected with miR-19
mimics for 48h in different concentration. (F) Relative growth rate of Jurkat cells after transfected with miR-19 inhibitors for 48h in different
concentration. Data in histograms are represented as mean±SD. T test, *P<0.05. **P<0.01 compared with the health (B), 293T (C), untreated
group (E and F). 50m: 50nM miR-19 mimics; 25m: 25nM miR-19 mimics; nm: negative mimics; tc: transfect reagent control; u: untreated group;
100i: 100nM miR-19 inhibitors; 50i: 50nM miR-19 inhibitors; ni: negative inhibitors.
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BCL2L11, CYLD and NOTCH1 were repressed. PTEN is
a tumor suppress gene and its down-regulation will
activate the PI3K/AKT signaling pathway in cancers
(56,57). In T-ALL patients, post-translational inactivation
of PTEN would cause incontrollable proliferation of T cell
(58,59). HOXA9 is one of the hub genes in our regulatory
network, and it was reported as a leukemogenic
homeoprotein in T-ALL (60). BCL2L11 is another hub
gene, transgenic studies in mouse suggested that
BCL2L11 acted as an essential initiator of apoptosis in
thymocyte-negative selection (61). Expression of
BCL2L11 can be induced by nerve growth factor, and
its dysregulation might lead to leukemia (62,63).
NOTCH1 plays a vital role in T-cell development and
transformation, and  50% T-ALL patients show
abnormal expression of NOTCH1 (64). Downstream tran-
scriptional targets of Notch1 include HES1 and MYC,
both of which can affect the PI3K/AKT and NF-kB-
signaling pathways. CYLD is a promising hub gene in
our network, which acts as a negative regulator of
NF-kB and JNK signaling (65). In summary, all the evi-
dences suggested that up-regulating of miR-19 will cause
the disorder of multiple T-ALL genes and implies strongly
carcinogenic potential.
Furthermore, the experimental results conﬁrmed the re-
liability of our regulatory network. CYLD was found with
low expression in T-ALL cell lines and with obvious dif-
ference comparing to healthy subjects. Down-regulation
of miR-19 can signiﬁcantly restore the expression of
Figure 5. MiR-19 inhibits CYLD and affects downstream NF-kB. (A) MiR-19 mimics decreased the expression level of CYLD in Jurkat, Molt-4
and HEK293T cells by western blot. (B) Expression level of CYLD was enhanced by miR-19 inhibitors in Jurkat, Molt-4, but no obvious effect in
HEK-293T cells. (C) The miR-19 mimics increased the downstream NF-kB P65 protein level in cell line nucleus. (D) NF-kB P65 expression level
decreased by miR-19 inhibitors in the tumor cell lines. (E) Sequence alignment of the miR-19a/b base-paring site in the 3’ UTR of CYLD mRNAs.
The region complementary to the miR-19 is highly conserved among ﬁve species (hsa: human, ptr: chimpanzee, mmu: mouse, rno: rat, and bta: cow.
The predicted binding site of miR-19 with CYLD target sequences are shown in boxes. (F) The miR-19 targeted the 30-UTR of CYLD mRNA by
luciferase reporter assay in HEK293T cells by transfected with miR-19 mimics/inhibitors/negative and reporter vector. Data are represented as
mean±SD. nc: negative control. T test, **P<0.01 compared with the negative control. The means of 50m, 25m, nm, tc, u, 100i, 50i and ni are the
same as described in Figure 4.
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would increase CYLD expression (Figure 5A and B).
High expression level of CYLD reduced the nuclear trans-
location of NF-kB signiﬁcantly and the IL-6 expression,
which was dependent on the activation of NF-kB. But the
decrease of IL-6 was less than NF-kB (P65), which
may ascribe to the balance of a relationship between the
classical and non-classical NF-kB pathway (66). Both
the TFBS prediction and UCSC ENCODE ChIP-Seq
data showed that there were potential NF-kB-binding
sites existing on promoters of CYLD and miR-19.
Therefore, CYLD, miR-19 and NF-kB participated in a
FFL, which provides a new mechanism of the sustained
activation of NF-kB in T-ALL and hematologic
malignancies.
Inspiringly, our regulatory network provided a
powerful tool to investigate mechanisms of T-ALL,
through which we may ﬁnd some potential therapeutic
targets. The ﬁrst potential therapeutic strategy is the
inhibition of miR-17–92 cluster, which might result in
elevated expression of BCL2L11, PTEN and CYLD,
and leukemia cells proliferation would be suppressed
and trend to apoptosis. It has been reported that gluco-
corticoids repress the expression of the microRNA cluster
miR-17–92 (67), which may be adopted as a safe mean for
inhibition of miR-17–92. The second therapeutic strategy
is the inhibition of NOTCH1-signaling pathway. Multiple
pathways were regulated by NOTCH1/HES1 in the
process of leukemogenesis, g-secretase inhibitors would
repress the NOTCH1 maturation and induce cell-cycle
arrest in T-ALL cell lines (64). The third therapeutic
approach is the inhibition of oncogenic PI3K/AKT/
mTOR pathway. The PI3K/AKT pathway was found
high-frequency abnormalities in T-ALL (59), and mTOR
inhibitor rapamycin showed promising effects in preclin-
ical models and Jurkat cell line (68,69).
In summary, our miRNA-TF co-regulatory network
analysis provided some core regulators and clues for the
Figure 6. A model of miR-19 and its targets involving in signaling pathways and regulatory network in T-ALL. Cell surface receptors activate
multiple signaling pathways, including Ras/MAPK cascade, PI3K/AKT, JAK and NOTCH signaling. These signal transductions trigger several
nucleus TFs such as STAT, NF-kB and CREB to regulate the transcription of miRNAs (e.g. miR-19) and T-ALL genes. Members of miR-17–92
cluster especially miR-19 inhibit tumor suppressor genes PTEN and CYLD. CYLD was a suppressor of NF-kB.
Nucleic Acids Research, 2012,Vol.40, No. 12 5211regulatory mechanisms of T-ALL. Furthermore, we ex-
perimentally validated one of the hub miRNAs and
hub genes in the network. We conﬁrmed that miR-19
regulated the CYLD expression and the existence of
miR-19-CYLD-NF-kB FFL in T-ALL. Consequently,
our study may provide potential therapeutic targets in
T-ALL and present a new strategy combined bioinfor-
matics analysis with experimental validation to study
complex diseases.
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